Objective: The aim of the study was to assess the evolution of clinical symptoms and vestibulocochlear function in patients with definite vestibular migraine (dVM).
Vestibular migraine (VM) is a frequent variant of migraine characterized by episodic vertigo that may be accompanied by auditory symptoms. Clinical features such as the variable duration of vertigo attacks and inconsistent temporal association with migrainous headaches have been well delineated in several case series. [1] [2] [3] [4] [5] Oculographic studies during the acute attack indicate that VM mostly originates from central vestibular structures and only rarely involves the labyrinth. 6, 7 Audio-vestibular testing in the symptom-free interval has shown mild interictal vestibular [1] [2] [3] [4] 8, 9 and cochlear 1,3,10 -12 abnormalities. Previous studies, however, have been limited to cross-sectional assessment. Longitudinal data on the evolution of clinical symptoms and vestibulo-cochlear findings, which may help distinguish VM from other vestibular disorders such as Ménière disease (MD), [13] [14] [15] are lacking. It is unknown whether vestibulo-cochlear function progressively deteriorates or whether interictal findings are reversible. Comparisons across studies are hampered by the lack of generally accepted diagnostic criteria. Our group has proposed clinical criteria for definite vestibular migraine (dVM) and probable vestibular mi-graine (pVM) 5 that are modeled on the International Classification of Headache Disorders (ICHD), 16 taking into account the specific features of vestibular symptoms in migraine. In a recent study, we evaluated the clinical validity of these criteria by reassessing 47 patients with dVM and 27 patients with pVM after an extended follow-up period of 5 to 11 years to confirm the initial diagnosis and exclude other causes for vertigo. 17 We now report on the evolution of clinical symptoms and vestibulocochlear function in 61 of the original 75 patients who met criteria for dVM after repeat neurotologic assessment on follow-up.
METHODS A follow-up assessment of clinical symptoms and vestibulo-cochlear findings was performed in 61 patients with dVM (54 women, 7 men; median age, 55 years; range, 24 -76 years) after a median follow-up of 9 years (range, 5.5-11 years). Patients who presented to our dizziness clinic between 1999 and 2004 and were diagnosed as dVM or pVM according to the following criteria 5 Patients with auditory symptoms at initial presentation were excluded if they fulfilled criteria for definite or probable MD according to the American Academy of Otolaryngology (AAO). 18 Of 127 eligible patients, 75 (n ϭ 47 with dVM, n ϭ 28 with pVM) were reached and consented to follow-up assessment. After re-evaluation, dVM was confirmed in 40 of 47 patients with an initial diagnosis of dVM and 14 of 28 patients with pVM. Seven patients met criteria for dVM except for sensorineural hearing loss that formally fulfilled AAO criteria for bilateral MD. All patients reported vertigo meeting MD criteria but also showed atypical vestibulo-cochlear symptoms, including symmetric, only mild or moderate hearing loss with a mainly down-sloping pattern involving the low-frequency range (mean hearing level at 0.5-3 kHz between 25 and 45 dB in both ears), but peaking in the high frequencies; prolonged attack duration of Ն3 days; or atypical vertigo with recurrent short spells of spontaneous or positional vertigo. 17 Although a coexistence of both disorders could not fully be excluded, the atypical hearing loss made MD highly improbable. Thus, VM was considered the likely diagnosis and these patients were also included. Fourteen patients were excluded because the initial diagnosis was revised (in 1 patient with a prior diagnosis of dVM and in 3 patients with pVM) or because patients still met criteria for only pVM (n ϭ 10). 17 The median duration of VM since onset of vertigo at follow-up was 12.7 years (range, 6.5-59 years). The last vertigo attack had occurred at a median of 14 days (range, 1 day to 10 years) before follow-up.
Both initial and follow-up assessment included a detailed interview covering clinical vertigo features, a history of ICHD migraine, and concomitant cochlear and migrainous symptoms. Patients compared frequency and severity of vertigo during the 12 months prior to follow-up to the time of their first visit. Previous and current use of migraine prophylaxis was documented.
Both initially and at follow-up, a standardized neurotologic bedside examination was performed in the symptom-free interval in all but 1 patient who initially presented with acute vertigo. Initial findings of this patient were excluded from analysis. The initial assessment was performed by 1 of 4 neurotologists (A.R., M.v.B., H.N., T.L.). All follow-up assessments were performed by A.R.
Neurotologic examination included testing for spontaneous nystagmus with and without Frenzel glasses, nystagmus provoked by head-shaking, positional nystagmus (PN) in the headhanging positions (head straight and turned 45°to each side) and in the left and right lateral supine positions, gaze-evoked nystagmus in the horizontal and vertical plane, vestibulo-ocular reflex (VOR) by head-thrusts in the horizontal plane, VOR suppression, smooth pursuit, and saccades. Balance tests included walking in a straight line (tandem walk), Romberg test, and tandem Romberg test (both feet in line).
Initially, complementary diagnostic procedures were performed according to clinical presentation. Pure-tone audiometry (PTA) was performed in all patients with cochlear symptoms (n ϭ 23) and 19 patients without clinical sign of cochlear involvement (total, 69%). Caloric testing was performed in 62% and cerebral MRI or CT in 72% of patients. At follow-up, PTA was performed in all patients. Bithermal caloric testing was performed in 45 patients (74%); for the remaining, caloric testing was refused (n ϭ 12), aborted (n ϭ 3), or not performed because of pregnancy (n ϭ 1).
Caloric testing was performed with the patient supine and head anteroflexed at 30°. Irrigation with hot (44°C) and cold (30°C) water was maintained for 30 seconds with a betweenstimuli interval of 5 minutes. Symmetry of peak angular slowphase velocity was analyzed according to the Jongkees formula. 19 Unilateral canal paresis (UCP) was assumed at a side difference Ͼ25%. Bilateral hyporesponsiveness was diagnosed when total slow-phase velocity of 4 irrigations was Ͻ20°/second, and bilateral hyperresponsiveness was diagnosed when total slow-phase velocity was Ͼ168°/second. 20 A peripheral vestibular dysfunction (PVD) was assumed when one of the following findings was present:
1. Direction-fixed, predominantly horizontal spontaneous or head-shaking nystagmus with an abnormal head-impulse test contralateral to the direction of the nystagmus 21 2. Positional nystagmus fulfilling criteria for canalolithiasis or cupulolithiasis 22,23 3. UCP or bilateral hyporesponsiveness on caloric testing A central vestibular or ocular motor dysfunction (COD) was assumed when 1 of the following findings was present: 1. Purely vertical or torsional spontaneous nystagmus 2. Horizontal-torsional nystagmus with normal head-impulse test on the side contralateral to the nystagmus 3. Positional nystagmus incompatible with canalolithiasis or cupulolithiasis 22,23 4. Gaze-evoked nystagmus 5. Impaired VOR suppression 6. Saccadic pursuit 7. Dysmetric or slow saccades Standard protocol approvals, registrations, and patient consents. The study was approved by the local ethics board. All patients gave informed consent before entering the study.
Statistical analysis. For statistical analyses, SPSS 18.0 was used. The 2 or Fisher test was applied to determine differences in nominal variables, and Student t test was used for differences in means. Multivariate logistic regression analysis was performed to test for associations of age, sex, duration of VM, and migraine syndrome with ocular motor abnormalities and balance function at follow-up. A 2-sided significance level of p Ͻ 0.05 was adopted.
RESULTS Evolution of clinical symptoms. The majority of patients (87%) still reported vertigo attacks during the 12 months before follow-up. Eight patients (13%) had been free of vertigo for a median duration of 6.6 years (range, 3-10 years). Twentytwo patients (36%) had previously taken migraine prophylaxis. Only 8 patients (13%), including 2 of the vertigo-free patients, were still on prophylaxis. Only 6 of 53 untreated patients (11%) had been vertigo-free in the previous year. All but 1 patient still had migraine headaches. Frequency of vertigo attacks was reduced in 56%, increased in 29%, and unchanged in 16% of patients (figure 1). Impact of vertigo was rated "mild" by 36%, "moderate" by 43%, and "severe" by 21% of those with persisting attacks. Impact was defined as "mild" when usual activities could be pursued, "moderate" when activities were sometimes abandoned, and "severe" when activities were often abandoned because of vertigo. Of working adults, 27% had been on sick leave because of vertigo in the previous year (median, 4 days; range, 2-90 days).
The proportion of patients with concomitant cochlear symptoms with vertigo had increased from 16% to 49%. While all patients reported migrainous symptoms with vertigo, 59% also had episodes of isolated vertigo. Table 1 summarizes clinical features of vertigo and accompanying migrainous and cochlear symptoms. Interictal dizziness during selfmotion or motion sickness were reported by 69%, visually induced dizziness or vertigo 24 by 54%, and mild, persistent unsteadiness by 18% of patients.
Neurotologic findings. Initially, 18% of patients showed at least 1 sign of PVD or COD. Ocular motor abnormalities were observed in 15% (table 2). The most frequent finding was positional PN (figure 2). Balance test findings were abnormal in 25% of patients, including pathologic tandem walk (n ϭ 6), Romberg test (n ϭ 6), or tandem Romberg test (n ϭ 15).
At follow-up, the proportion of patients with PVD or COD had increased to 47.5%, including ocular motor abnormalities in 41% (table 2). The most common finding was PN (28%), including definite central-type PN in 18% (figure 2). One patient showed PN typical of posterior-canal benign paroxysmal positional vertigo. Five patients had slow, low-amplitude unidirectional horizontal PN, of undetermined origin, under Frenzel glasses. Balance was abnormal in 54% of patients, including pathologic tandem walk (n ϭ 25), Romberg test (n ϭ 12), or tandem Romberg test (n ϭ 33).
Only 1 of 9 patients with initial ocular motor abnormalities had similar findings of a central-type PN on follow-up. One patient with initial PVD showed central PN, and 1 patient with initial central-type PN showed PN typical of posterior-canal benign par- oxysmal positional vertigo on follow-up. In 6 patients ocular motor function had turned to normal. The proportion of ocular motor abnormalities or pathologic balance tests at follow-up did not differ significantly between men and women or patients with migraine with and without aura in univariate analysis. There was no association of age, sex, duration of VM since onset, or type of migraine with ocular motor abnormalities, in multivariate analysis ( p Ͼ 0.05 for all variables included). Balance abnormalities were weakly associated with older age (odds ratio, 1.07; 95% CI, 1.01-1.13) but not with sex, duration of VM, or migraine syndrome. Caloric responses. Initially, 2 of 38 patients with caloric testing had UCP (5%). At follow-up, 7 of 45 patients had UCP (16%), 2 showing a side difference Ͼ50%, including 1 with a corresponding pathologic head-impulse test. Two patients showed bilateral caloric hyporesponsiveness, and another 2 showed bilateral hyperresponsiveness.
Audiometric findings. On follow-up, 11 patients (18%) showed bilateral sensorineural hearing loss with a downsloping pattern, involving the low frequencies. Seven of them had cochlear symptoms and hearing loss that formally met AAO criteria for bilateral MD (figure 3), but clinical features were atypical of MD (see Methods). One patient with bilateral low-frequency loss but without aural symptoms met criteria for basilar-type migraine. Three patients had very mild low-frequency hearing loss that did not meet MD criteria. Twenty-seven patients had bilateral high-frequency loss, and 1 had mild unilateral conductive hearing loss. DISCUSSION This study assesses the evolution of clinical symptoms and vestibulo-cochlear findings in patients with VM after an extended follow-up. The majority (87%) continued to have recurrent vertigo, which was associated with at least moderate impact in more than half. Although frequency and severity Aural fullness 13 26 Hearing loss 12 26 Cochlear symptoms in the interval a 26 77
Tinnitus 20 69
Aural fullness 3 2 5
Hearing loss 15 38 Sudden hearing loss 10 of vertigo had decreased in half of the patients, twothirds still experienced disabling vertigo with disruption of daily activities. However, only a few patients were taking migraine prophylaxis at follow-up. This is in line with previous findings from our population-based survey that most VM patients do not receive treatment despite substantial disability. 25 However, the efficacy of migraine prophylaxis in VM has never been shown in a randomized controlled trial, which may explain the reluctance of physicians to use this option. There was an overall increase of interictal vestibulo-cochlear dysfunction at follow-up. The proportion of patients with COD, PVD, and pathologic balance tests had more than doubled. Nearly half of the patients (41%) showed ocular motor abnormalities. The most common finding was PN, mostly of central origin (18%). These findings are suggestive of progressive vestibular dysfunction in almost half of our patients. However, our results also indicate that ocular motor dysfunction may vary over time, since only 1 of 9 patients showed similar findings on initial and follow-up examinations. As an alternative explanation, the abnormalities observed in the symptom-free interval may partly reflect delayed recovery of vestibular function after an acute vertigo attack.
Our data confirm the results of cross-sectional studies reporting high rates of COD or PVD in 47% to 70% of patients with VM. 1, 4, 9 Caloric abnormalities in our series lie within the lower range of previous estimates, reporting UCP in 8% to 22% [1] [2] [3] [4] 8, 9, 12, 26, 27 and bilateral vestibular failure in up to 11% 1, 3, 9, 27 of patients with VM. Considerably higher rates of UCP have been reported in basilartype migraine (55%-60%). 12, 26, 27 UCP in our patients rarely exceeded 50%, which is similar to caloric findings in MD. 28, 29 Likewise, the head-impulse test often remains normal in both disorders, even at longer follow-up. 4, 29 Hyperresponsive caloric responses in our series fall within the lower range of previous estimates (up to 19% of patients with VM). 1, 9, 10, 30 Reports on interictal COD in VM have varied considerably from 8.6% to 66% of patients, [1] [2] [3] [4] 8, 9, 27 some of the differences presumably owing to variable definitions of VM and testing protocols. A recent cross-sectional study in 30 patients with dVM according to our criteria found COD in 23% of patients, including 10% central-type PN. 9 A large study that assessed interictal ocular motor function in 90 patients with VM, examining 59% of patients at least twice over a period of 2 to 7 years, found a high proportion of COD similar to ours (66%), including central PN in 11%. Ocular motor abnormalities varied over time but did not completely disappear. Diagnostic criteria, however, were less strict than our definition of dVM. 4 Higher rates of COD in patients with basilar type migraine, including central-type PN in 86%, have been reported. 12 Based on a significantly higher rate of saccadic dysmetria in patients with basilar-type migraine vs patients with pVM or dVM (40% vs 13%), a spectrum of disease severity has been suggested. 27 The high rate of interictal COD matches the findings in acute VM attacks. In our study in 20 patients with acute dVM or pVM, oculographic findings suggested a central origin of vestibular symptoms in 50% and a peripheral origin in 15% but were indeterminate in 35% of patients. Forty percent showed PN. 6 A recent study found central PN in all 26 patients examined during an acute VM attack. 7 Thus, both ictal and interictal central-type PN may provide an additional clue in diagnosing patients with episodic vertigo. Since central-type nystagmus is clearly not caused by peripheral vestibular disorder, it should raise suspicion of VM as a potential cause of recurrent vertigo when other central causes of vertigo have been excluded.
Our data corroborate the previously reported overlap of vestibulo-cochlear symptoms in VM and MD. [13] [14] [15] Half of our patients experienced cochlear symptoms with vertigo. Seven patients had developed bilateral sensorineural hearing loss meeting AAO criteria for MD. However, whereas hearing levels in MD typically drop to a mean level of 50 -60 dB within 5-10 years, 28 cochlear loss in our patients remained mild after a similar follow-up. In addition, hearing loss was bilaterally symmetric, which is rare in MD, occurring in only 2% in the beginning, whereas sequential bilateral cochlear loss affects up to 50% of patients at longer follow-up. 28 Mild cochlear loss with low-frequency involvement has been re- Origin of ocular motor abnormalities in the symptom-free interval at initial presentation (n ‫؍‬ 60) and on follow-up (n ‫؍‬ 61) ported in 3% to 12% of patients with VM 1,3,10,11 and 80% of patients with basilar-type migraine. 12 Our longitudinal data indicate that hearing loss in VM progresses much more slowly than in MD. However, the current AAO guidelines 18 do not sufficiently discriminate the 2 disorders. Several pathophysiologic mechanisms may explain how migraine may cause both central and peripheral vestibulo-cochlear dysfunction. Hypotheses include modulation of vestibular afferents by neurotransmitters released during migraine attacks 2,31 as well as transient ischemia in the inner ear and brainstem due to a vasospasm. 4, 32 The vascular hypothesis has recently gained novel support from the findings of the CAMERA study, showing an association of migraine with aura and subclinical ischemic lesions in the posterior circulation territory. 33 Because VM shares clinical features with other paroxysmal disor-ders such as familial hemiplegic migraine 34 and episodic ataxia type 2, 35 for which genetic mutations of ion channels have been identified, 36, 37 deficient ion channels that are expressed both in the inner ear and in the brain could lead to endolymphatic hydrops 32, 38 and central vestibular dysfunction. Analyses of candidate genes, however, have been negative in VM so far. 38, 39 This study provides a longitudinal assessment of clinical symptoms and vestibulo-cochlear function in VM based on previously validated diagnostic criteria. 17 Diagnostic certainty was increased by repeat neurotologic assessment to rule out other causes of vertigo that had become apparent during follow-up. There are some limitations to be considered. Since vertigo in our patients was severe enough to prompt a visit to a specialized dizziness clinic, our findings may not be representative of VM in the general popula- Examples of bilateral sensorineural hearing loss in 3 of 7 patients with low-frequency involvement that formally met criteria for Ménière disease, according to the guidelines of the American Academy of Otolaryngology, at follow-up
Hearing loss in all 7 patients showed a mainly downsloping pattern and only mild to moderate low-frequency hearing loss (mean hearing level at 0.5-3 kHz between 25 and 45dB in both ears). White circles indicate hearing thresholds at initial presentation; black circles: hearing thresholds at follow-up.
tion. Bedside examination may have missed subtle ocular motor abnormalities such as mild saccade inaccuracy. Evolution of clinical symptoms was enquired about retrospectively, and recall bias cannot be excluded. The majority of VM patients continue to have recurrent vertigo, and the impact of vertigo may remain high. The overall increase of interictal vestibular abnormalities suggests slowly progressive deterioration of vestibular function in about half of patients. Auditory symptoms are frequent, but cochlear impairment remains mild. Interictal centraltype PN may provide an additional clue to VM in patients with recurrent vertigo and may help to distinguish it from purely peripheral vestibular disorders such as MD. Controlled trials with migraine prophylaxis are needed to improve long-term outcome in severely affected patients.
